Disposition of quinapril and quinaprilat in the isolated perfused rat kidney
dc.contributor.author | Kugler, Alan R. | en_US |
dc.contributor.author | Olson, Stephen C. | en_US |
dc.contributor.author | Smith, David E. | en_US |
dc.date.accessioned | 2006-09-11T15:36:48Z | |
dc.date.available | 2006-09-11T15:36:48Z | |
dc.date.issued | 1995-06 | en_US |
dc.identifier.citation | Kugler, Alan R.; Olson, Stephen C.; Smith, David E.; (1995). "Disposition of quinapril and quinaprilat in the isolated perfused rat kidney." Journal of Pharmacokinetics and Biopharmaceutics 23(3): 287-305. <http://hdl.handle.net/2027.42/45050> | en_US |
dc.identifier.issn | 0090-466X | en_US |
dc.identifier.issn | 1573-8744 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/45050 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=8834197&dopt=citation | en_US |
dc.description.abstract | An isolated perfused rat kidney model was used to probe the renal disposition of quinapril and quinaprilat after separate administration of each drug species. Control studies were performed with drug-free perfusate ( n=8 ) and perfusate containing quinapril ( n=9 ) quinaprilat ( n=7 ) at initial drug concentrations of 1000 ng/ml (including corresponding tracer levels of tritiated drug). Physiologic parameters were within the normal range of values for this technique and were stable for the duration of each experiment. Quinapril and quinaprilat concentrations were determined in perfusate, urine, and perfusate ultrafiltrate using a specific and sensitive reversed-phase HPLC procedure with radiochemical detection, coupled to liquid scintillation spectrometry. Perfusate protein binding was determined using an ultrafiltration method at 37°C. The total renal learance of quinapril ( CLr ) was calculated as Dose/AUC (0-∞), and is represented by the sum of its urinary and metabolic clearances. The urinary clearances ( CLe ) of quinapril and quinaprilat were calculated as urinary excretion rate divided by midpoint perfusate concentration for each respective species. Of the total renal clearance for quinapril ( CLr =4.49 ml/min), less than 0.1% was cleared as unchanged drug ( CLe =0.004 ml/min); over 99% of the drug was cleared as quinaprilat formed in the kidney. The clearance ratio of quinapril [ CR=CLr/(fu·GFR )] was 41.0, a value representing extensive tubular secretion into the renal cells. Following quinaprilat administration, the clearance ratio of metabolite [ CR=CLe/(fu β GFR) ] was 3.85, indicating a net secretion process for renal elimination. | en_US |
dc.format.extent | 1019385 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Kluwer Academic Publishers-Plenum Publishers; Plenum Publishing Corporation ; Springer Science+Business Media | en_US |
dc.subject.other | Quinapril | en_US |
dc.subject.other | Clearance | en_US |
dc.subject.other | Biochemistry, General | en_US |
dc.subject.other | Pharmacy | en_US |
dc.subject.other | Biomedicine | en_US |
dc.subject.other | Pharmacology/Toxicology | en_US |
dc.subject.other | Veterinary Medicine | en_US |
dc.subject.other | Biomedical Engineering | en_US |
dc.subject.other | Quinaprilat | en_US |
dc.subject.other | Isolated Perfused Rat Kidney | en_US |
dc.subject.other | Renal Disposition | en_US |
dc.title | Disposition of quinapril and quinaprilat in the isolated perfused rat kidney | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Pharmacy and Pharmacology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | College of Pharmacy and Upjohn Center for Clinical Pharmacology, 3705 Upjohn Center, The University of Michigan, 48109-0504, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Department of Pharmacokinetics and Drug Metabolism, Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, 48106-1047, Ann Arbor, Michigan; College of Pharmacy and Upjohn Center for Clinical Pharmacology, 3705 Upjohn Center, The University of Michigan, 48109-0504, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationother | Department of Pharmacokinetics and Drug Metabolism, Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, 48106-1047, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 8834197 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/45050/1/10928_2006_Article_BF02354286.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1007/BF02354286 | en_US |
dc.identifier.source | Journal of Pharmacokinetics and Biopharmaceutics | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.